Patient P-03497
Therapy response
Unstable
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
15%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S05
- Day 104 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 104.
Primary contributors, last 14 days
- Inflammatory activity-7
- GI instability-5
- Nutritional resilience+4
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log4.9/10
stable · -0.0 vs previous 14 d
Stress level
Daily log2.9/10
worsening · +0.2 vs previous 14 d
Pessimism score
Daily log3.8/10
stable · +0.2 vs previous 14 d
Sleep quality
Wearable42.8/100
stable · +1.6 vs previous 14 d
Libido
Daily log5.4/10
stable · -0.2 vs previous 14 d
HRV
Wearable61 ms
stable · -0.0 vs previous 14 d
Toxicity
Blood18.8/100
worsening · +2.5 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 68 from the failing basin, 49 from restoration.
Good elements to keep
- Protein (supports)perturbation · steering +8.5
- Butyrate producers intacthidden · steering +7.5
- Proteinsupporter · GI -4.8 next day
Main detractors to watch
- Lactoseperturbation · steering -12.4
- Alcoholperturbation · steering -8.4
- Rapid metabolizerhidden · steering -8
- Bacteroides fragilis elevatedhidden · steering -7.4
- Lactosedetractor · GI +6.8 next day
- Alcoholdetractor · GI +5.4 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Lactose+6.8detractor · 95%
- Alcohol+5.4detractor · 89%
- Protein-4.8supporter · 95%
- Dietary fat load-2no signal · 33%
- Histamine load+1no signal · 15%
- Caffeine+0.8no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
- Autonomic recovery ↓20
- WearableShort sleep window
- Mucosal barrier integrity ↓10
- WearableSleep 5.8 h, below personal baseline
DNA
Fictional pharmacogenomic panel
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 3.2 · butyrate capacity 61/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 63 ms
- Sleep
- 6.2 h
- Steps
- 4,898
- Resting HR
- 69 bpm
Daily log: GI score 17, nutritional resilience 67, adherence 85.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03034 | 55% | S14 | AD-05 | no change | 30 |
| P-03369 | 51% | S18 | AD-05 | no change | 37 |
| P-03380 | 49% | S16 | AD-05 | improved | 34 |
| P-03122 | 47% | S13 | AD-05 | no change | 40 |
| P-03129 | 45% | S18 | AD-05 | no change | 32 |
| P-03158 | 45% | S17 | AD-05 | no change | 37 |
| P-03424 | 43% | S12 | AD-05 | improved | 41 |
| P-03104 | 41% | S14 | AD-05 | no change | 27 |
| P-03204 | 39% | S16 | AD-05 | improved | 48 |
| P-03441 | 38% | S19 | AD-05 | improved | 37 |
| P-03111 | 37% | S07 | AD-05 | no change | 48 |
| P-03351 | 34% | S07 | AD-05 | no change | 51 |